RAMIPRIL
Hypertension With Metabolic Syndrome
NovartisSmall moleculePhase 4 / ApprovedDormant
B
61/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 46/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Hypertension With Metabolic Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
AMLODIPINE Novartis | Phase 4 | BB |
Aliskiren Novartis | Phase 4 | CCC |
Same molecule, other indications
RAMIPRIL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →